SBIR Phase I: Defining the Multimodal Signature of Stroke

这个小企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力属于健康信息学的重大挑战范围。对于急性中风的管理和治疗有很好的方案，然而，这些方案只有在患者进入医疗保健系统后才有效。然而，卫生保健提供者与患者的互动有限，这些互动发生在临床设置的高度受限的环境中。医生对病人行为的控制有限，在临床之外识别中风症状的能力也有限。对于高卒中风险的患者，目前没有可用的系统来监测卒中症状并实时启动响应。因此，有必要远程监测患者，而目前的中风反应系统无法提供覆盖。提出的解决方案将扩大提供中风症状监测患者的日常生活。跟踪患者的日常生活将大大丰富我们对中风的认识，并将扩展到监测其他神经和神经精神障碍和疾病。这个小企业创新研究（SBIR）第一阶段项目致力于中风的实时检测。缺血性中风影响了70万美国人，每年造成的损失约为330亿美元，是美国第五大死亡原因和致残原因。静脉组织纤溶酶原激活剂（tPA）自1995年以来一直是FDA批准的治疗方法，但只有5-10%的符合条件的患者接受这种治疗。初始卒中症状后到达急诊室的时间与tPA和血管内治疗后更好的预后直接相关，这些治疗的时间窗分别为4.5小时和24小时。尽管开展了大规模的公共卫生运动，但识别中风症状和启动应急响应系统仍然是一项重大挑战。该项目的目标是开发和测试一种可穿戴和计算解决方案，以有效地提醒缺血性中风患者并及时启动应急响应。该解决方案将包括一个具有多种模式的可穿戴设备，这些设备将被馈送到智能手机和基于云的分析系统，用于实时分析和检测。一旦部署，该设备有望显著改善卒中应急反应，并增加接受静脉注射tPA和其他再灌注治疗的患者数量。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project falls within the scope of the grand challenges in health informatics. There are excellent protocols for the management and treatment of acute stroke, however, these protocols are only effective once patients have been admitted into the healthcare system. Health care providers, however, have limited interaction with their patients, and these interactions occur in the highly constrained environment of the clinical setting. Physicians have limited control over patient behavior and limited ability to recognize stroke symptoms outside the clinical setting. For patients with high stroke risk, there is currently no system available to monitor stroke symptoms and initiate a response in real-time. Thus, there is a need to monitor patients remotely, where the current systems for stroke response fail to provide coverage. The proposed solution will expand the provision of stroke symptom monitoring to the daily lives of patients. Tracking patients as they go through their daily lives will considerably enrich our knowledge of stroke and will allow extension to monitoring for other neurological and neuropsychiatric disorders and diseases. This Small Business Innovation Research (SBIR) Phase I project addresses the real-time detection of stroke. Ischemic stroke affects 700,000 Americans, costs approximately $33 billion annually, and is the fifth leading cause of death and a leading cause of disability in the US. IV tissue plasminogen activator (tPA) has been an FDA approved therapy since 1995, yet only 5-10% of eligible patients receive this therapy. Arrival time in the emergency room after initial stroke symptoms is directly associated with better outcomes after tPA and endovascular therapy, with a time window of 4.5 hours and 24 hours for these treatments, respectively. Despite massive public health campaigns, identifying symptoms of stroke and activating emergency response systems remains a major challenge. The goal of this project is to develop and test a wearable and computational solution to effectively alert ischemic stroke victims and initiate emergency response in a timely manner. The solution will consist of a wearable device with multiple modalities, which are fed to a smartphone and a cloud-based analysis system for real-time analysis and detection. Once deployed, the device is expected to dramatically improve stroke emergency response and increase the number of patients receiving IV tPA and other reperfusion therapies.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.